Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
G. P. Kim
No relevant relationships to disclose
N. R. Foster
No relevant relationships to disclose
M. Salim
No relevant relationships to disclose
P. J. Flynn
No relevant relationships to disclose
D. F. Moore
No relevant relationships to disclose
R. Zon
No relevant relationships to disclose
R. B. Mowat
No relevant relationships to disclose
M. Wiesenfeld
No relevant relationships to disclose
A. E. McCullough
No relevant relationships to disclose
S. R. Alberts
No relevant relationships to disclose